AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15957134
Drug: Immediate-Treatment Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-Treatment Group (ITG)
Trial: 15957134
Drug: Deferred-Treatment Group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred-Treatment Group (DTG)
Trial: 12107244
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (80 mU/m(2).min) during euglycemic clamp
Trial: 12107244
Drug: Matched saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched saline infusion (control group)
Trial: 7554700
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg loratadine every morning plus 500 mg erythromycin stearate every 8 hours
Trial: 7554700
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg loratadine every morning plus placebo every 8 hours
Trial: 7554700
Drug: placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo every morning plus 500 mg erythromycin stearate
Trial: 6243916
Drug: Topical ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ampicillin sodium
Trial: 30566417
Drug: Second-generation oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second-generation oral antipsychotics
Trial: 28363637
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg DSM265 1 day before CHMI
Trial: 28363637
Drug: Atovaquone-proguanil (250-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone-proguanil (250-100 mg) 1 day before CHMI
Trial: 28363637
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg DSM265 7 days before CHMI
Trial: 21378389
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (target glucose 80‐120 mg/dl)
Trial: 21378389
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose control (target glucose 180 mg/dl or less)
Trial: 29549863
Drug: Appetite Awareness
RxNorm normalized name: APPETITE SUPPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appetite Awareness Treatment (AAT)
Trial: 26130657
Drug: Land-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Land-based therapy (Control group, n=14), 45 minutes per session, five days a week for four weeks
Trial: 23632946
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta (IFNβ)‐1a
Trial: 18621519
Drug: Formoterol 12
RxNorm normalized name: formoterol 12 mcg inhalation capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol 12 microg twice daily for 5 days
Trial: 16085366
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) and contingency management (CM)
Trial: 12888042
Drug: 0.25 mg/ml
RxNorm normalized name: thiram 0.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/ml ICG
Trial: 12888042
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml ICG
Trial: 12888042
Drug: 1.25 mg/ml
RxNorm normalized name: menthol 1.25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg/ml ICG
Trial: 12888042
Drug: Control (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.25 mg/ml and 0.5 mg/ml ICG)
Trial: 10472355
Drug: Photon therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photon therapy (median dose 60 Gy, range 45 to 65 Gy)
Trial: 10472355
Drug: Neutron therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutron therapy (median dose 14.1 Gy, range 5.0 to 18.57 Gy)
Trial: 10472355
Drug: Mixed-beam irradiation
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-beam irradiation (average dose 36.5 Gy photon and 8.5 Gy neutrons)
Trial: 8923090
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interferon gamma 100 ug subcutaneously daily for up to 21 days
Trial: 6760063
Drug: 4.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg/kg theophylline solution administered at 9 a.m.
Trial: 6760063
Drug: 4.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg/kg theophylline solution administered at 9 p.m.
Trial: 6760063
Drug: 4.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 mg/kg theophylline solution (both morning and evening)
Trial: 30017826
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of vilanterol (25 μg) + fluticasone furoate (100 μg)
Trial: 14703410
Drug: Gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene therapy + radiotherapy (GTRT group, n = 16)
Trial: 8538479
Drug: Estradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol valerate (EV, 2 mg/day for 21 days) with cyproterone acetate (CPA, 1 mg/day in the last 10 days of the treatment cycle)
Trial: 8538479
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (500 mg/day)
Trial: 7333345
Drug: Theolair Retard
RxNorm normalized name: diclofenac sodium Extended Release Oral Tablet [Lofensaid Retard]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theolair Retard 250 mg sustained release tablet
Trial: 30419858
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy added to chemo-radiotherapy
Trial: 23135413
Drug: Cementless fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cementless fixation with screw augmentation (n=45)
Trial: 20193089
Drug: Yoga practice
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yoga practice for one hour daily for one week
Trial: 18072052
Drug: 1 L
RxNorm normalized name: BLUE 1 LAKE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 L of polyethylene glycol (PEG) solution
Trial: 18072052
Drug: 2 L
RxNorm normalized name: H-2 locus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 L of polyethylene glycol (PEG) solution
Trial: 18072052
Drug: Clear liquid
RxNorm normalized name: Ensure Clear Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clear liquid diet and overnight fast (no PEG solution)
Trial: 16271342
Drug: 6‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mg nicotine enemas
Trial: 16271342
Drug: 6‐mg nicotine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6‐mg nicotine enemas in patients taking mesalamine
Trial: 11583888
Drug: GTN, 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN, 0.6 mg/h/24 h for six days
Trial: 9622211
Drug: Bemiparin (therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bemiparin (therapeutic subcutaneous doses)
Trial: 7888287
Drug: Metoprolol CR/Z0K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/Z0K 100 mg
Trial: 7888287
Drug: Metoprolol CR/Z0K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/Z0K 50 mg
Trial: 3352163
Drug: Branched-chain amino
RxNorm normalized name: Branched-chain amino acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain amino acids (BCAA) infusion
Trial: 28835380
Drug: BL-8040 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-8040 (1 mg/kg)
Trial: 28835380
Drug: BL-8040 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-8040 (0.5 mg/kg)
Trial: 28835380
Drug: BL-8040 (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-8040 (0.75 mg/kg)
Trial: 23669458
Drug: Programs with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programs with culturally responsive policies and assessment and treatment practices
Trial: 17226044
Drug: Tibolone (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (21 days treatment)
Trial: 15490767
Drug: Couple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple therapy included in inpatient treatment (15 patients)
Trial: 15490767
Drug: Standard inpatient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard inpatient treatment without partner therapy (16 patients)
Trial: 11902819
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (oestradiol 2 mg and norethisterone acetate 1 mg per day)
Trial: 24235081
Drug: Velcalcetide 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velcalcetide 0.5 mg
Trial: 24235081
Drug: Velcalcetide 2
RxNorm normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velcalcetide 2 mg
Trial: 24235081
Drug: Velcalcetide 5
RxNorm normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velcalcetide 5 mg
Trial: 24235081
Drug: Velcalcetide 10
RxNorm normalized name: Velcalcetide
DrugBank: Etelcalcetide (DB12865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Velcalcetide 10 mg
Trial: 22777096
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A control vaccine (n = 102)
Trial: 12891099
Drug: Stripping and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stripping and high ligation (S&L)
Trial: 10561349
Drug: Dartmouth regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dartmouth regimen (dacarbazine 220 mg/m², cisplatin 25 mg/m² days 1 to 3, carmustine 150 mg/m² day 1 every other cycle, tamoxifen 10 mg orally bid)
Trial: 10561349
Drug: Dacarbazine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dacarbazine 1,000 mg/m²
Trial: 8556879
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor treatment (OST)
Trial: 8556879
Drug: Oral sensorimotor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sensorimotor treatment (OST) and Chewing exercises
Trial: 8369192
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of iohexol (9 mg I/ml)
Trial: 8369192
Drug: Viscous preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscous preparation of iohexol (9 mg I/ml)
Trial: 8369192
Drug: Aqueous solution
RxNorm normalized name: Zephiran Chloride 1:750 Antiseptic Aqueous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solution of amidotrizoate (9 mg I/ml)
Trial: 8369192
Drug: Aqueous solutions
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous solutions of iohexol and amidotrizoate
Trial: 11464232
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (oral antioxidant dietary supplement)
Trial: 9290026
Drug: (THY 1-)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (THY 1-) fibroblasts non-containing lipids producing insulin-like growth factor 2 (ILGF 2), binding proteins 2 and 4, and epidermal growth factor receptors
Trial: 26268636
Drug: Irbesartan 100 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan 100 mg/day and amlodipine 5 mg/day (Irb/Am group)
Trial: 26268636
Drug: Valsartan 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg/day and amlodipine 5 mg/day (Val/Am group)
Trial: 25178072
Drug: Fixed irbesartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed irbesartan/amlodipine combination 150/5 mg
Trial: 25178072
Drug: Fixed irbesartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed irbesartan/amlodipine combination 150/10 mg
Trial: 25178072
Drug: Fixed irbesartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed irbesartan/amlodipine combination 300/5 mg
Trial: 25178072
Drug: Fixed irbesartan/amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed irbesartan/amlodipine combination 300/10 mg
Trial: 25178072
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with irbesartan/amlodipine combinations
Trial: 22412063
Drug: Antiviral hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral hand treatment containing 2% citric acid and 2% malic acid in 62% ethanol (applied every 3 hours while awake)
Trial: 22412063
Drug: Antiviral hand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral hand treatment
Trial: 20696083
Drug: Iota-Carrageenan nasal
RxNorm normalized name: iota-Carrageenan
DrugBank: iota-Carrageenan (DB15304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iota-Carrageenan nasal spray (0.12%) in saline solution, three times daily for 4 days
Trial: 15669890
Drug: Risperidone up
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone up to 6 mg/day
Trial: 24746956
Drug: Voucher-based reinforcement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voucher-based reinforcement therapy (VBRT)
Trial: 8877926
Drug: Etidronate 400
RxNorm normalized name: etidronate 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate 400 mg/day for 2 weeks followed by a 13 week drug-free period for a total of 120 weeks
Trial: 28629738
Drug: Oral sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sedation (hydrocodone/acetaminophen and lorazepam)
Trial: 17211861
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel (35 mg/m2 on Days 1, 8, and 15 of a 4-week cycle) plus cisplatin (75 mg/m2 on Day 1)
Trial: 17211861
Drug: 3-weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-weekly docetaxel (75 mg/m2 on Day 1) plus cisplatin (75 mg/m2 on Day 1)
Trial: 11871190
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) at doses of 100 to 2000 micrograms daily
Trial: 11871190
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) at a two-fold increased dose
Trial: 7611862
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin‐1 receptor antagonist (100 mg loading dose, followed by continuous infusion of 1.0 mg/kg per hour or 2.0 mg/kg per hour)
Trial: 7611862
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin‐1 receptor antagonist (high dose)
Trial: 77369
Drug: Routine skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine skin preparation with 70% isopropyl alcohol for 5 seconds
Trial: 77369
Drug: No skin
RxNorm normalized name: Aveeno Skin Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No skin preparation before insulin injection
Trial: 31419483
Drug: Gentamicin 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 240 mg plus azithromycin 2 g
Trial: 31419483
Drug: Ceftriaxone 500
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 500 mg plus azithromycin 2 g
Trial: 31402005
Drug: Chlorination at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorination at the point of collection using solid tablet chlorine doser (treatment group)
Trial: 28026906
Drug: Successful H.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful H. pylori eradication therapy
Trial: 23888317
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of encapsulated fish oil (providing 600 mg/day of EPA + DHA) for 9 weeks
Trial: 18046534
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin (40 mg/kg)
Trial: 18046534
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin (50 mg/kg)
Trial: 18046534
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin (60 mg/kg)
Trial: 18046534
Drug: Intravenous amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous amikacin (15 mg/kg)
Trial: 10936473
Drug: Limb compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Limb compression bandage (e.g., Unna's boot) applied weekly
Trial: 3903784
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g aluminium hydroxide and 1.6 g magnesium hydroxide per day
Trial: 30540640
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion group
Trial: 30567725
Drug: 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 of IV decitabine on days 1 to 10
Trial: 30567725
Drug: 1.3 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.3 mg/m2 of subcutaneous bortezomib on days 1, 4, 8, and 11 for up to 4 10-day cycles followed by monthly 5-day cycles
Trial: 30567725
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of decitabine and bortezomib
Trial: 26857443
Drug: Solubilized vaginal
RxNorm normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 10-μg
Trial: 26857443
Drug: Solubilized vaginal
RxNorm normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solubilized vaginal estradiol softgel capsule (TX-004HR) at 25-μg
Trial: 26857443
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol tablet (Vagifem®) at 10-μg
Trial: 26857443
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol tablet (Vagifem®) at 25-μg
Trial: 19238517
Drug: Lamotrigine 325
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine 325 mg
Trial: 19238517
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid 1,250 mg
Trial: 17410456
Drug: Leukocytapheresis (LCAP)
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytapheresis (LCAP) weekly for 5 weeks
Trial: 17410456
Drug: Leukocytapheresis (LCAP)
RxNorm normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukocytapheresis (LCAP) monthly after initial treatment
Trial: 17410456
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (Control) after initial remission
Trial: 15369805
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (1 microM)
Trial: 11600586
Drug: Acetaminophen (4000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4000 mg/d)
Trial: 30395791
Drug: Engaged4Life program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Engaged4Life program (technology-assisted self-monitoring of daily activity via pedometers and daily tablet-based surveys; psychoeducation + goal-setting via a 3-hour workshop; peer mentoring via phone 2×/week for 2.5 weeks)
Trial: 28978327
Drug: Abiraterone/prednisone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abiraterone/prednisone with continuing LHRH therapy